CN Patent

CN111615514B — 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物

Assigned to Orri Bio Pharmaceutical Co ltd · Expires 2022-10-11 · 4y expired

What this patent protects

本文提供式I化合物及其互变异构体和可药用盐和溶剂合物，其中R 1 、R 2 和R 3 具有说明书中所给出的含义，所述化合物为RET激酶的抑制剂，可用于治疗和预防可用RET激酶抑制剂治疗的疾病，包括RET相关的疾病和病症。

USPTO Abstract

本文提供式I化合物及其互变异构体和可药用盐和溶剂合物，其中R 1 、R 2 和R 3 具有说明书中所给出的含义，所述化合物为RET激酶的抑制剂，可用于治疗和预防可用RET激酶抑制剂治疗的疾病，包括RET相关的疾病和病症。

Drugs covered by this patent

Patent Metadata

Patent number
CN111615514B
Jurisdiction
CN
Classification
—
Expires
2022-10-11
Drug substance claim
No
Drug product claim
No
Assignee
Orri Bio Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.